Various factors can activate EMT in PF, including endoplasmic reticulum stress injury, TGF-β—the target of pirfenidone, an effective drug in PF treatment—and β-catenin, a crucial factor promoting pulmonary fibrosis (40–43). This evidence concerns the gene TGFB1 and pulmonary fibrosis.